[1]朱海龙,王俊.黄芪注射液联合高通量血液透析对尿毒症患者肾功能和血清微RNA-155、白细胞介素-17、超敏C反应蛋白水平的影响[J].新乡医学院学报,2023,40(1):073-78.[doi:10.7683/xxyxyxb.2023.01.013]
　ZHU Hailong,WANG Jun.Effect of astragalus injection combined with high-flux hemodialysis on renal function and serum microRNA-155,interleukin-17 and hypersensitive C-reactive protein levels of patients with uremia[J].Journal of Xinxiang Medical University,2023,40(1):073-78.[doi:10.7683/xxyxyxb.2023.01.013]
点击复制

黄芪注射液联合高通量血液透析对尿毒症患者肾功能和血清微RNA-155、白细胞介素-17、超敏C反应蛋白水平的影响
分享到：

《新乡医学院学报》[ISSN:1004-7239/CN:41-1186/R]

卷:
40卷
期数:
2023年1期
页码:
073-78
栏目:
临床研究
出版日期:
2023-01-05

文章信息/Info

Title:
Effect of astragalus injection combined with high-flux hemodialysis on renal function and serum microRNA-155,interleukin-17 and hypersensitive C-reactive protein levels of patients with uremia
作者:
朱海龙; 王俊
（长安医院肾病科，陕西　西安　710016）
Author(s):
ZHU Hailong; WANG Jun
(Department of Nephrology,Chang′an Hospital,Xi′an 710016,Shaanxi Province,China)
关键词:
尿毒症; 黄芪注射液; 高通量血液透析; 肾功能; 微RNA-155; 白细胞介素-17; 超敏C反应蛋白
Keywords:
uremia; astragalus injection; high-flux hemodialysis; renal function; microRNA-155; interleukin-17; hypersensitive C-reactive protein
分类号:
R692.5
DOI:
10.7683/xxyxyxb.2023.01.013
文献标志码:
A
摘要:
目的　探讨黄芪注射液联合高通量血液透析（HFHD）对尿毒症患者肾功能及血清微RNA-155（miR-155）、白细胞介素-17（IL-17）、超敏C反应蛋白（hs-CRP）水平的影响。方法　选择2016年12月至2019年12月长安医院收治的156例尿毒症患者为研究对象，根据治疗方法将患者分为观察组（n=86）和对照组（n=70）。2组患者均给予积极治疗原发疾病、纠正贫血及进食低盐、富含优质蛋白质类食物等常规治疗措施；在常规治疗基础上，对照组患者给予HFHD治疗，观察组患者给予黄芪注射液和HFHD联合治疗。治疗前及治疗3、6个月，测量患者舒张压（DBP）和收缩压（SBP），检测患者血尿素氮（BUN）、血肌酐（SCr）、前白蛋白（PA）、白蛋白（Alb）、血红蛋白（Hb）、IL-17和hs-CRP及miR-155水平，并测量患者24 h尿量和24 h尿蛋白。治疗6个月后评估2组患者临床疗效。结果　治疗前2组患者DBP、SBP、SCr、BUN水平及24 h尿蛋白、24 h尿量比较差异无统计学意义（P>0.05），2组患者治疗3、6个月后DBP、SBP、SCr、BUN水平及24 h尿蛋白、24 h尿量显著低于治疗前（P<0.05），2组患者治疗6个月后DBP、SBP、SCr、BUN水平及24 h尿蛋白、24 h尿量显著低于治疗3个月（P<0.05）；治疗3、6个月后，观察组患者DBP、SBP、SCr、BUN水平及24 h尿蛋白显著低于对照组，24 h尿量显著高于对照组（P<0.05）。治疗前2组患者PA、Alb、Hb水平比较差异无统计学意义（P>0.05）。观察组患者治疗3、6个月后PA、Alb、Hb水平显著高于治疗前（P<0.05）；对照组患者治疗3、6个月后Hb水平显著高于治疗前（P<0.05）；对照组患者治疗3、6个月后PA、Alb水平与治疗前比较差异无统计学意义（P>0.05）；2组患者治疗6个月后Hb水平显著高于治疗3个月（P<0.05）；2组患者治疗6个月后PA、Alb水平与治疗3个月比较差异无统计学意义（P>0.05）。治疗3、6个月后，观察组患者PA、Alb、Hb水平显著高于对照组（P<0.05）。治疗前2组患者血清IL-17、hs-CRP水平及miR-155相对表达量比较差异无统计学意义（P>0.05）。2组患者治疗3、6个月后血清IL-17、hs-CRP水平及miR-155相对表达量显著低于治疗前（P<0.05）；2组患者治疗6个月后血清IL-17、hs-CRP水平及miR-155相对表达量显著低于治疗3个月（P<0.05）。治疗3、6个月后，观察组患者IL-17、hs-CRP水平及miR-155相对表达量显著低于对照组（P<0.05）。观察组和对照组患者治疗总有效率分别为93.02%（80/86）、74.29%（52/70），观察组患者治疗总有效率显著高于对照组（χ2=10.408，P<0.05）。结论　黄芪注射液和HFHD联合治疗可有效控制尿毒症患者的血压，抑制炎症反应，延缓肾功能损伤，改善营养状况。
Abstract:
Objective　To investigate the effect of astragalus injection combined with high-flux hemodialysis (HFHD) on renal function and serum microRNA-155 (miR-155),interleukin-17 (IL-17) and hypersensitive C-reactive protein (hs-CRP) levels of patients with uremic.Methods　A total of 156 uremic patients admitted to Chang′an Hospital from December 2016 to December 2019 were selected as the study subjects,and the patients were divided into the observation group (n=86) and control group (n=70) according to the treatment methods.The patients in the both groups were given routine treatment measures such as actively treating the primary disease,correcting anemia,eating low salt and high quality protein foods.On the basis of routine treatment,the patients in the control group were treated with HFHD,and the patients in the observation group were treated with astragalus injection and HFHD.Before treatment and after 3 and 6 months of treatment,the levels of diastolic blood pressure (DBP),systolic blood pressure (SBP),blood urea nitrogen (BUN),serum creatinine (SCr),prealbumin (PA),albumin (Alb),hemoglobin (Hb),IL-17,hs-CRP,miR-155,24-hour urine volume and 24-hour urine protein were measured.The clinical efficacy of patients in the two groups was evaluated after 6 months of treatment.Results　There was no significant difference in the levels of DBP,SBP,SCr,BUN,24-hour urine protein and 24-hour urine volume between the two groups before treatment (P>0.05).The levels of DBP,SBP,SCr,BUN,24-hour urine protein and 24-hour urine volume of patients in the both groups after 3 and 6 months of treatment were significantly lower than those before treatment (P<0.05).The levels of DBP,SBP,SCr,BUN,24-hour urine protein and 24-hour urine volume of patients in the both groups after 6 months of treatment were significantly lower than those after 3 months of treatment (P<0.05).Compared with the control group,the levels of DBP,SBP,SCr,BUN and 24-hour urine protein of patients in the observation group decreased significantly,and 24-hour urine volume increased significantly after 3 and 6 months of treatment (P<0.05).There was no significant difference in the levels of PA,Alb and Hb between the two groups before treatment (P>0.05).The levels of PA,Alb and Hb of patients after 3 and 6 months of treatment were significantly higher than those before treatment in the observation group (P<0.05).The level of Hb of patients after 3 and 6 months of treatment was significantly higher than that before treatment in the control group (P<0.05).There was no significant difference in the levels of PA and Alb after 3,6 months of treatment and before treatment in the control group (P>0.05).The Hb level of patients in the two groups after 6 months of treatment was significantly higher than that after 3 months of treatment (P<0.05).There was no significant difference in the levels of PA and Alb after 6 months of treatment and 3 months of treatment in the two groups (P>0.05).After 3 and 6 months of treatment,the levels of PA,Alb and Hb in the observation group were significantly higher than those in the control group (P<0.05).There was no significant difference in serum IL-17,hs-CRP levels and the relative expression of miR-155 between the two groups before treatment (P>0.05).The levels of serum IL-17,hs-CRP levels and the relative expression of miR-155 after 3 and 6 months of treatment were significantly lower than those before treatment in the both groups (P<0.05).The serum IL-17,hs-CRP levels and the relative expression of miR-155 after 6 months of treatment were significantly lower than those after 3 months of treatment in the both groups (P<0.05).After 3 and 6 months of treatment,the levels of serum IL-17,hs-CRP and the relative expression of miR-155 in the observation group were significantly lower than those in the control group (P<0.05).The total effective rate of patients in the observation group and the control group was 93.02% (80/86) and 74.29% (52/70),respectively.The total effective rate of patients in the observation group was significantly higher than that in the control group (χ2=10.408,P<0.05).Conclusion　The combination of astragalus injection and HFHD can effectively control the blood pressure,inhibit inflammatory reaction,delay renal function damage,and improve nutritional status in patients with uremic.

参考文献/References:

［1］　毛伟君，陈仙芳，王艳萍，等.红光照射对尿毒症患者血液透析动静脉内瘘感染的影响［J］.中华医院感染学杂志，2018，28（3）：375-379.
MAO W J,CHEN X F,WANG Y P,et al.Effects of red light irradiation on arteriovenous fistula infection in hemodialysis patients with uremic［J］.Chin J Nosocomiol,2018,28(3):375-379.
［2］　JUNG S W,KIM D R,CHO K S,et al.Effects of dialysate acidification with citrate versus acetate on cell damage,uremic toxin levels,and inflammation in patients receiving maintenance hemodialysis［J］.Am J Kidney Dis,2019,73(3):432-434.
［3］　LI G J,AI B C,ZHANG W H,et al.Efficacy and safety of astragalus injection combined with western medicine in the treatment of early diabetic nephropathy:a protocol for systematic review and meta-analysis［J］.Medicine(Baltimore),2021,100(12):e25096.
［4］　中国中西医结合学会肾脏疾病专业委员会.慢性肾衰竭中西医结合诊疗指南［J］.河北中医，2016，38（2）：313-317.
KIDNEY DISEASE PROFESSIONAL COMMITTEE OF CHINESE SOCIETY OF INTEGRATED TRADITIONAL CHINESE AND WESTERN MEDICINE.Guidelines for diagnosis and treatment of chronic renal failure with integrated traditional Chinese and western medicine［J］.Hebei J TCM,2016,38(2):313-317.
［5］　国家中医药管理局.中医病证诊断疗效标准［M］.南京：南京大学出版社，2017：48-49.
NATIONAL ADMINISTRATION OF TRADITIONAL CHINESE MEDICINE.Diagnostic efficacy standard of TCM syndrome［M］.Nanjing:Nanjing University Press,2017:48-49.
［6］　PURI I,SHIRAZI N M,YAP E,et al.Intestinal dialysis for conservative management of uremia［J］.Curr Opin Nephrol Hypertens,2020,29(1):64-70.
［7］　FAVRETTO G,CUNHA R S D,DALBONI M A,et al.Endothelial microparticles in uremia:biomarkers and potential therapeutic targets［J］.Toxins(Basel),2019,11(5):267.
［8］　张洪源，林小堃.高通量血液透析联合尿毒清对老年终末期肾病患者细胞免疫的影响［J］.实用医学杂志，2018，34（2）：273-276.
ZHANG H Y,LIN X K.Effect of high fluxes of hemodialysis combined with Niaoduqing granuleson on cell-mediated immunity in old patient［J］.J Pract Med,2018,34(2):273-276.
［9］　JI C L,LUO Y M,ZOU C,et al.Effect of astragaloside IV on indoxyl sulfate-induced kidney injury in mice via attenuation of oxidative stress［J］.BMC Pharmacol Toxicol,2018,19(1):53.
［10］　陈培贤，陈苑兰.黄芪注射液对尿毒症血液透析患者残余肾功能的影响［J］.现代诊断与治疗，2019，30（11）：1806-1808.
CHEN P X,CHEN Y L.Effect of astragalus injection on residual renal function in uremic hemodialysis patients［J］.Mod Diagn Treat,2019,30(11):1806-1808.
［11］　侯静静，徐慕娟，黄俊城，等.黄芪注射液治疗脓毒症患者前后免疫细胞及细胞因子水平变化［J］.辽宁中医杂志，2018，45（9）：1876-1878.
HOU J J,XU M J,HUANG J C,et al.Changes of immune cells and cytokines before and after astragalus injection treatmentof patients with sepsis［J］.Liaoning J Tradit Chin Med,2018,45(9):1876-1878.
［12］　LIU B S,MIAO J X,PENG M F,et al.Effect of 3∶7 ratio of astragalus total saponins and curcumin on the diabetic nephropathy rats model［J］.Saudi J Biol Sci,2019,26(1):188-194.
［13］　GIUSEPPE M,GIANNINA A,ELISA C,et al.Natalizumab therapy modulates miR-155,miR-26a and proinflammatory cytokine expression in MS patients［J］.PLoS One,2016,11(6):e0157153.
［14］　马玲，云鹏.血液透析与血液灌流疗法改善糖尿病肾病透析者微炎症状态的作用［J］.重庆医学，2017，46（6）：767-769.
MA L,YUN P.A controlled study of hemodialysis combined with hemoperfusion for the treatment of microinflammation in diabetic nephropatby［J］.Chongqing Med,2017,46(6):767-769.
［15］　关昌杰，何凤，周姗姗，等.miR-155调控Smad5促进糖尿病肾病肾脏纤维化作用［J］.实用医学杂志，2017，33（20）：3340-3344.
GUAN C J,HE F,ZHOU S S,et al.The role of miR-155 in the pathogenesis of diabetic nephropathy by regulation of Smad5［J］.J Pract Med,2017,33(20):3340-3344.
［16］　LI G H,MA H J,YIN Y Y,et al.CRP,IL-2 and TNF-α level in patients with uremia receiving hemodialysis［J］.Mol Med Rep,2018,17(2):3350-3355.
［17］　闫二萍，邱模炎，任建伟，等.不同灸疗方案对血液透析患者营养不良的影响［J］.中华中医药杂志，2017，32（5）：2233-2236.
YAN E P,QIU M Y,REN J W,et al.Impact of different moxibustion schemes on malnutrition of hemodialysis patients［J］.Chin J Tradit Chin Med Pharm,2017,32(5):2233-2236.

相似文献/References:

[1]曹中亮.尿毒症出血治疗方法简评[J].新乡医学院学报,1987,4(02):075.
[2]赵素香,石淑兰.黄芪注射液联合1 ,6 ———二磷酸果糖辅治小儿病毒性心肌炎58 例[J].新乡医学院学报,2000,17(05):391.
[3]刘民英,杨溯玲.／肾移植受者尿液可溶性白介素Ⅱ受体的动态监测及其意义[J].新乡医学院学报,2000,17(01):027.
[4]陈 娟,吕文国.黄芪注射液联合复方丹参注射液治疗急性脑梗死30例[J].新乡医学院学报,2002,19(02):083.
[5]杨磊,刘雅楠,许清玉,等.35例非透析治疗尿毒症性心功能不全[J].新乡医学院学报,2002,19(06):498.
[6]杨磊,刘雅楠,许清玉,等.35例非透析治疗尿毒症性心功能不全[J].新乡医学院学报,2002,19(06):498.
[7]刘有才.黄芪注射液治疗老年心力衰竭疗效观察[J].新乡医学院学报,2005,22(03):244.
[8]高军华,千智斌.黄芪注射液预处理对大鼠急性心肌缺血再灌注损伤的保护作用[J].新乡医学院学报,2016,33(10):856.[doi:10.7683/xxyxyxb.2016.10.005]
　GAO Jun-hua,QIAN Zhi-bin.Protective effect of Astragalus injection preconditioning on acute myocardial ischemia-reperfusion injury in rats[J].Journal of Xinxiang Medical University,2016,33(1):856.[doi:10.7683/xxyxyxb.2016.10.005]
[9]班艳娜,甄乾娜,傅惠佳.高效液相色谱荧光法检测血浆中硫醇物的方法学研究[J].新乡医学院学报,2018,35(6):459.[doi:10.7683/xxyxyxb.2018.06.003]
　BAN Yan-na,ZHEN Qian-na,FU Hui-jia.Methodology research of determination of thiols in plasma by high performance liquid chromatography with fluorescence[J].Journal of Xinxiang Medical University,2018,35(1):459.[doi:10.7683/xxyxyxb.2018.06.003]

更新日期/Last Update: 2023-01-05